Pharmaceutical Pricing, Reimbursement & Market Access

Lanton Strategies International advises pharmaceutical and biotechnology companies on how U.S. and European drug pricing, reimbursement and market access policies affect commercialization, launch planning and long-term revenue strategy.

U.S. drug pricing and reimbursement

We assess Medicare Part B and Part D, Medicaid drug rebate policy, the 340B Drug Pricing Program, pharmacy benefit manager (PBM) regulation and commercial payer developments. We help manufacturers understand how these policies may affect coverage, distribution, contracting and patient access.

Market access and launch strategy

We support European and U.S. life sciences companies in evaluating reimbursement pathways, policy exposure and distribution considerations before entering new markets. Our advisory work connects government policy and regulatory developments with commercial planning.

International pricing and trade

We examine how most-favored-nation pricing proposals, international reference pricing, trade measures and changes to national reimbursement systems may affect cross-border launch sequencing and commercial strategy.

Our advisory services

  • Drug pricing and reimbursement policy analysis

  • Medicare, Medicaid, 340B and PBM policy assessment

  • Market access and commercialization risk assessment

  • International drug pricing and trade policy analysis

  • Executive briefings and government affairs strategy

For pharmaceutical pricing and market access advisory inquiries, contact LSI.